NR

Neurosense Therapeutics LtdNASDAQ NRSN Stock Report

Last reporting period —

Updated 25 Nov, 2024

Last price

Market cap $B

0.024

Micro

Exchange

XNAS - Nasdaq

NRSN Stock Analysis

NR

Uncovered

Neurosense Therapeutics Ltd is uncovered by Eyestock quantitative analysis.

Market cap $B

0.024

Dividend yield

Shares outstanding

11.674 B

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

View Section: Eyestock Rating